Abstract
The day-to-day responsibility of caring for a person with dementia often exacts a toll upon the caregiver, which may be manifested psychologically, physically, socially and financially.
The last decade has witnessed the advent of drug availability for the treatment of Alzheimer’s disease, specifically the cholinesterase inhibitors. Caregivers are integral to the initiation, administration and monitoring of treatment. In particular, they provide substitute informed consent when patients are no longer competent to do so. While there is evidence that cholinesterase inhibitors may reduce caregiver burden and time spent assisting patients, there are also burdens associated with being the person responsible for administering medication.
Caregivers are key to research into the use of medications for Alzheimer’s disease. They have roles in recruitment and consent and monitoring response and adverse effects. Increasingly, caregivers themselves are recognised as legitimate targets for evaluating the efficacy of new pharmacological agents for Alzheimer’s disease (as benefits have been demonstrated for them).
Caregivers have responsibilities regarding the drug treatment of patients with Alzheimer’s disease, and require information about the medications so that they can have realistic expectations. Doctors need to work in partnership with care-givers and patients when prescribing drugs for Alzheimer’s disease.
Similar content being viewed by others
References
Barer BM, Johnson CL. A critique of the caregiving literature. Gerontologist 1990; 30(1): 26–9
Consumer Health Sciences. Princeton (NJ): LLC, Dec 1999. Alzheimer’s caregiver project methodology [online]. Available at URL: http://www.chsinternational.com/methodology_alzheimers_caregiver_project.asp
Brodaty H, Hadzi-Pavlovic D. Psychosocial effects on care-givers of living with persons with dementia. Aust N Z J Psychiatry 1990; 24: 351–61
Baumgarten M, Battista RN, Infante-Rivard C, et al. The psychological and physical health of family members caring for an elderly person with dementia. J Clin Epidemiol 1992; 45(1): 61–70
Grafström M, Winblad B. Family burden in the care of the demented and nondemented elderly — a longitudinal study. Alzheimer Dis Assoc Disord 1995; 9(2): 78–86
Gonzalez-Salvador MT, Arango C, Lyketsos CG, et al. The stress and psychological morbidity of the Alzheimer patient caregiver. Int J Geriatr Psychiatry 1999; 14(9): 701–10
Wright LK, Hickey JV, Buckwalter KC, et al. Emotional and physical health of spouse caregivers of persons with Alzheimer’s disease and stroke. J Adv Nurs 1999; 30: 552–63
Stephens MA, Ogrocki PK, Kinney JM. Sources of stress for family caregivers of institutionalized patients. J Appl Gerontol 1991; 10(3): 328–42
Schulz R, Vistainer P, Williamson GM. Psychiatric and physical morbidity effects of caregiving. J Gerontol 1990; 45: P181–91
Haley WE, Levine EG, Brown SL, et al. Stress, appraisal, coping and social support as predictors of adaptational outcome among dementia caregivers. Psychol Aging 1987; 2: 323–30
Schulz R, Williamson GM. The measurement of caregiver outcomes in Alzheimer disease research. Alzheimer Dis Assoc Disord 1997; 11(6): 117–24
Brodaty H. The family and drug treatments for Alzheimer’s disease. In: Gauthier S, editor. Pharmacotherapy of Alzheimer’s disease. London: Martin Dunitz, 1998: 123–39
Braekhus A, Oksengard AR, Engedal K, et al. Social and depressive stress suffered by spouses of patients with mild dementia. Scand J Prim Health Care 1998; 16: 242–6
Max W. Cost of illness of dementia. In: Health economics of dementia. Chichester: Wiley, 1998: 197–206
Leon J, Neumann PJ, Hermann RC, et al. Health-related quality-of-life and service utilization in Alzheimer’s disease: a cross sectional study. Am J Alzheimers Dis 2000; 15(2): 94–108
Max W, Webber PA, Fox PJ. Alzheimer’s disease: the unpaid burden of caring. J Aging Health 1995; 7: 179–99
Mace NK, Rabins PV. The 36-hour day. Baltimore (MD): Johns Hopkins University Press, 1991
Langa KM, Chernew ME, Kabeto MU, et al. National estimates of the quantity and cost of informal caregiving for the elderly with dementia. J Gen Intern Med 2001; 16: 770–8
Brodaty H, McGilchrist C, Harris L, et al. Time until institutionalization and death in patients with dementia: role of care-giver training and risk factors. Arch Neurol 1993; 50: 643–50
Morycz RK. Caregiving strain and the desire to institutionalise family members with Alzheimer’s disease. Res Aging 1985; 7: 329–61
Annerstedt L, Elmstahl S, Ingvad B, et al. Family caregiving in dementia — an analysis of the caregiver’s burden and the “breaking-point” when home care becomes inadequate. Scand J Public Health 2000; 28: 23–31
Waite LM, Broe GA, Grayson DA, et al. The incidence of dementia in an Australian community population: the Sydney Older Persons Study. Int J Geriatr Psychiatry 2001; 16: 680–9
Alafuzoff, I Soininen, H. Neuropathology and ethiopathogenesis of Alzheimer’s disease. In: Qizilbash N, Schneider L, Chui H, et al., editors. Evidence-based dementia practice. Oxford: Blackwell, 2002: 244–59
Francis PT, Palmer AM, Snape M, et al. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry 1999; 66: 137–47
Cummings J. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000; 157: 4–15
Qizilbash N, Birks J, Lopez Arrieta J, et al. Tacrine for Alzheimer’s disease (Cochrane Review). Available in the Cochr-ane Library. Updated quarterly. The Cochrane Collaboration; issue 2. Oxford: Oxford Update Software, 2001
Winblad B, Engedal MD, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489–95
Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 1998; 50: 136–45
Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer’s disease-results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237–44
Mohs R, Doody R, Morris JL, et al. Donepezil preserves functional status in Alzheimer’s disease patients: results from a 1-year prospective placebo-controlled study. Eur Neuro-psychopharmacol 1999; 9 Suppl. 5: S328
Doody RS. Clinical profile of donepezil in the treatment of Alzheimer’s disease. Gerontology 1999; 45 Suppl. 1: 23–32
Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001; 57: 613–20
Farlow M, Anand R, Messina J, et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer’s disease. Eur Neurol 2000; 44: 236–41
Birks JS, Grimley Evans J, Iakovidou V, et al. Rivastigmine for Alzheimer’s disease (Cochrane review). Available in the Cochrane Library. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Oxford Update Software, 2001
McKeith IG, Grace JB, Walker Z, et al. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry 2000; 15: 387–92
Olin J, Schneider L. Systematic review of galantamine for Alzheimer’s disease (Cochrane review). Available in the Cochrane Library. Updated quarterly. The Cochrane Collaboration; issue 1. Oxford: Oxford Update Software, 2001
Zajaczkowski W, Quack G, Danysz W. Infusion of (+)-MK-801 and metamine — contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur J Pharmacol 1996; 296: 239–46
Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best study. Int J Geriatr Psychiatry 1999; 14(2): 135–46
Reisberg B, Windscheif U, Ferris SH, et al. Memantine in moderately severe to severe Alzheimer’s disease (AD): results of a placebo-controlled 6-month trial [abstract]. Neurobiol Aging 2000; 21(1S): S275
Orgogozo JM, Rigaud AS, Stöffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002; 33: 1834–9
Wilcock G, for the MMM 500 trial group. Cognitive improvement my memantine in a placebo-controlled trial in mild to moderate vascular dementia (the MMM 500 trial) [online]. Poster presented at the 6th International Springfield Symposium on Advances in Alzheimer Therapy; 2000 Apr 5–8; Stockholm, Sweden. Available at URL: http://www.memant-ine.com/inhalte/s1.html
Tariot PN, Blazina L. The psychopathology of dementia. In: Morris JC, editor. Handbook of dementing illnesses. New York: Marcel Dekker, 1994: 461–75
Peisah C, Brodaty H. Pharmacological management of challenging behaviours in people with dementia. Geriatric Therapeutics 1997; 27(1): 49–57
Fillit HM, Gutterman EM, Brooks RL. Impact of donepezil on caregiving burden for patients with Alzheimer’s disease. Int Psychogeriatr 2000; 12(3): 389–401
Shikiar R, Shakespeare A, Sagnier P-P, et al. The impact of metrifonate therapy on caregivers of patients with Alzheimer’s disease: results from the MALT clinical trial. J Am Geriatr Soc 2000; 48: 268–74
Tariot PN, Truyen L. Galantamine reduces the distress of caregivers of Alzheiimer’s disease patients [abstract]. Proceedings of the 10th Congress of the International Psycho-geriatrics Association (IPA); 2001 Sep 9–14; Nice, France. Int Psychogeriatr 2001; 13(S2): P348
Mastey V, Wimo A, Winblad B, et al. Donepezil reduces the time caregivers spend providing care: results of a one-year, double-blind, randomized trial in patients with mild to moderate Alzheimer’s disease [abstract]. J Am Geriatr Soc 2001; 49(4): S20
Lilienfeld S, Gaens E. Galantamine alleviates caregiver burden in Alzheimer’s disease: a 12 month study. Poster presented at the 5th Congress of the European Federation of Neurological Societies; 2000 Oct 14–18: Copenhagen, Denmark. Eur J Neurol 2000; 7 (Suppl. 3): P3111
Clipp EC, Moore MJ. Caregiver time use: an outcome measure in clinical trial research on Alzheimer’s disease. Clin Pharmacol Ther 1995; 58(2): 228–36
Hinchliffe A, Katona C, Livingstone G. The assessment and management of behavioural manifestations of dementia: a review and results of a controlled trial. International Journal of Psychiatry in Clinical Practice 1997; 1(13): 157–68
Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Tacrine Study Group. Neurology 1996; 47(1): 166–77
McRae T, Knopman D, Duttagupta S, et al. Donepezil delays time to nursing home placement [abstract]. J Am Geriatr Soc 2001; 49(4): S132
Brodaty H, Grossman F, Bruynseels J, et al. Risperidone in the treatment of agitation and psychosis of dementia. Proceedings of the 10th Congress of the International Psychogeriatrics Association; 2001 Sep 9–14: Nice, France. Int Psychogeriatr 2001; 13(S2): S108
Ranelli PL, Aversa SL. Medication-related stressors among family caregivers. Am J Hosp Pharm 1994; 51(1): 75–9
Green A, Brodaty H. Care-giver interventions. In: Qizilbash N, Schneider L, Chui H, et al., editors. Evidence-based dementia practice. Oxford: Blackwell Publishing, 2002: 764–94
Brodaty H, Green A, Koschera A. Evidence bases for interventions for caregivers of people with dementia [abstract]. J Neurol Sci 2001; 187 Suppl. 1: S118
Rockwood K, MacKnight C. Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials. Neuroepidemiology 2001; 20(2): 51–6
Bent S, Saint S, Vittinghoff E, et al. Antibiotics in acute bronchitis: a meta-analysis. Am J Med 1999; 107(1): 62–7
Brodaty H, Gresham M. Effect of a training programme to reduce stress in caregivers of patients with dementia. BMJ 1989; 299: 1375–9
Brodaty H, Gresham M, Luscombe G. The Prince Henry Hospital Dementia Caregivers’ Training Programme. Int J Geriatr Psychiatry 1997; 12: 183–92
Mittelman MS, Ferris SH, Steinberg G, et al. An intervention that delays institutionalisation of Alzheimer’s disease patients: treatment of spouse-caregivers. Gerontologist 1993; 33(6): 730–40
Mittelman MS, Ferris SH, Shulman E, et al. A comprehensive support group program: effect on depression in spouse-caregivers of AD patients. Gerontologist 1995; 35: 792–802
Mittelman MS, Ferris SH, Shulman E, et al. A family intervention to delay nursing home placements of patients with Alzheimer’s disease: a randomized controlled trial. JAMA 1996; 276(21): 1725–31
Mittelman MS, Brodaty H, Burns A. A multinational clinical trial of the effectiveness of a combined psychosocial and pharmacological intervention for AD patients and family caregivers. Proceedings of the World Alzheimer Congress; 2000 July 9–13; Washington (DC)
Acknowledgements
Henry Brodaty has been a sponsored speaker, advisory board member and/or consultant for Eisai Janssen, Lundbeck Novartis and Pfizer. He has also been paid to conduct clinical trials of medications by Janssen and Novartis. No sources of funding were used in the preparation of this manuscript.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brodaty, H., Green, A. Defining the Role of the Caregiver in Alzheimer’s Disease Treatment. Drugs Aging 19, 891–898 (2002). https://doi.org/10.2165/00002512-200219120-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002512-200219120-00001